ASX:PYC PYC Therapeutics (PYC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About PYC Therapeutics Stock (ASX:PYC) 30 days 90 days 365 days Advanced Chart Get PYC Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationA$611.26 millionP/E RatioN/ADividend Yield9.46%Price TargetN/AConsensus RatingN/A Company Overview PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia. Read More Receive PYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PYC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PYC Stock News HeadlinesPYC Therapeutics Advances Clinical Trials for PKD TreatmentJuly 6 at 8:36 PM | tipranks.comPYC Therapeutics Advances Phelan-McDermid Syndrome ProgramJune 26, 2025 | tipranks.comTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything. | Paradigm Press (Ad)PYC Therapeutics Advances VP-001 with FDA Trial Design ApprovalJune 22, 2025 | tipranks.comPYC Therapeutics Advances Clinical Trial for PKD TreatmentMay 25, 2025 | tipranks.comPYC Therapeutics Unveils Promising Trial Results for Retinitis Pigmentosa TreatmentMay 1, 2025 | tipranks.comPYC Therapeutics Reports Positive Clinical Trial Results for Eye Disease TreatmentApril 27, 2025 | tipranks.comPYC Therapeutics Secures $146 Million in Entitlement Offer to Advance RNA TherapiesApril 16, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PYC CIKN/A Webpyctx.com Phone61 8 6151 0992FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$37.73 million Net Margins-171.02% Pretax MarginN/A Return on Equity-68.34% Return on Assets-37.83% Debt Debt-to-Equity Ratio1.38 Current Ratio9.40 Quick Ratio8.93 Sales & Book Value Annual SalesA$22.06 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares4,670,000,000Free FloatN/AMarket CapA$611.26 million OptionableNot Optionable Beta0.71 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (ASX:PYC) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PYC Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share PYC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.